Although modest, MYC’s effects on PD-L1 expression had dramatic tumor regression consequences, consistent with minor immune regulator influences markedly impacting outcomes.17 In summary, the thiram and oHSV combination demonstrated enhanced antitumor efficacy and immune modulation versus oHSV monotherapy. The gene discussed is CD274; the disease is neoplasm.